Home › Research › Biomarkers
Associations of Anthropometry Measures Across 35 Years With Late-Life Plasma P-tau217 and Dementia
Ekaterina Zotcheva, Bjørn Heine Strand, Anita Lenora Sunde, Kay Deckers, Dag Aarsland, Nicholas James Ashton, Henrik Zetterberg, Vegard Skirbekk et al.. Neurology, 2026-06-02
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
The final study sample comprised 8,797 participants (53.5% women, mean age at HUNT4 77.8 [SD 6.2]). Of these, 2,649 (30.1%) were p-tau217-positive and 659 (7%) had biomarker-verified AD dementia. Midlife WtHR ≥0.60 was associated with 12.8% (95% CI 7.3-19.7) higher late-life p-tau217 concentration and higher risk of positive p-tau217 (relative risk ratios [RRRs] 1.55, 1.21-1.99) and biomarker-verified AD dementia (RRR 1.84, 1.27-2.65) compared with WtHR <0.50. In late life, WtHR ≥0.60 was associated with 15.6% (-19.0 to -12.2) lower p-tau217 concentration and lower risk of positive p-tau217 (RRR 0.49, 0.41-0.59) and biomarker-verified AD dementia (RRR 0.63, 0.46-0.86). BMI showed similar patterns: Midlife obesity was associated with higher p-tau217 concentration and elevated risk of biomarker-verified AD dementia, whereas late-life overweight/obesity was associated with lower p-tau217 and decreased risk of biomarker-verified AD dementia. Among those with positive p-tau217 or biomarker-verified AD dementia, mixed-effects regression showed higher midlife adiposity, reversing by late life. Our results identify midlife central and general adiposity as modifiable risk factors for AD pathology and AD dementia. WtHR may aid early risk stratification and inform interventions targeting central fat reduction.
What this study adds
Evidence grade: Low
The record lists 8,797 participants. Midlife central and general adiposity were linked to higher late-life p-tau217 and higher risk of biomarker-verified AD dementia, while late-life adiposity showed the opposite pattern. Reported effect size: 53.5%; 30.1%; 12.8%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Zotcheva, E., Strand, B. H., Sunde, A. L., Deckers, K., Aarsland, D., Ashton, N. J., et al. (2026). Associations of Anthropometry Measures Across 35 Years With Late-Life Plasma P-tau217 and Dementia. Neurology. https://doi.org/10.1212/wnl.0000000000218093
Vancouver
Zotcheva E, Strand BH, Sunde AL, Deckers K, Aarsland D, Ashton NJ, et al. Associations of Anthropometry Measures Across 35 Years With Late-Life Plasma P-tau217 and Dementia. Neurology. 2026. doi:10.1212/wnl.0000000000218093. PMID: 42228892.
BibTeX
@article{zotcheva2026-42228892,
author = {Zotcheva, Ekaterina and Strand, Bjørn Heine and Sunde, Anita Lenora and Deckers, Kay and Aarsland, Dag and Ashton, Nicholas James and Zetterberg, Henrik and Skirbekk, Vegard and others},
title = {{Associations of Anthropometry Measures Across 35 Years With Late-Life Plasma P-tau217 and Dementia}},
journal = {Neurology},
year = {2026},
doi = {10.1212/wnl.0000000000218093},
pmid = {42228892},
url = {https://doi.org/10.1212/wnl.0000000000218093}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- The final study sample comprised 8,797 participants (53.5% women, mean age at HUNT4 77.8 [SD 6.2]).
- Of these, 2,649 (30.1%) were p-tau217-positive and 659 (7%) had biomarker-verified AD dementia.
- Midlife WtHR ≥0.60 was associated with 12.8% (95% CI 7.3-19.7) higher late-life p-tau217 concentration and higher risk of positive p-tau217 (relative risk ratios [RRRs] 1.55, 1.21-1.99) and biomarker-verified AD dementia (RRR 1.84, 1.27-2.65) compared with WtHR <0.50.
- In late life, WtHR ≥0.60 was associated with 15.6% (-19.0 to -12.2) lower p-tau217 concentration and lower risk of positive p-tau217 (RRR 0.49, 0.41-0.59) and biomarker-verified AD dementia (RRR 0.63, 0.46-0.86).
- BMI showed similar patterns: Midlife obesity was associated with higher p-tau217 concentration and elevated risk of biomarker-verified AD dementia, whereas late-life overweight/obesity was associated with lower p-tau217 and decreased risk of biomarker-verified AD dementia.
Why it matters
Midlife central and general adiposity were linked to higher late-life p-tau217 and higher risk of biomarker-verified AD dementia, while late-life adiposity showed the opposite pattern. The authors identify midlife central and general adiposity as modifiable risk factors for AD pathology and dementia.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants8,797
- Effect size53.5%; 30.1%; 12.8%
- Evidence strengthLow
How this study scored 51/100
Published in a leading specialty journal. Scored zero for study design and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 3 / 4 | 8,797 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.5 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 3 / 6 | Cited 4.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Geir Selbæk: h-index 61 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 27 institution(s) in 9 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42228892) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 51 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 14.
Related studies in Biomarkers from nearby years
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.